This document provides guidance for the evaluation of new medicinal products in the treatment of ulcerative colitis. It clarifies the requirements for clinical documentation needed to support a marketing authorisation, the selection of patients, the recommended methods to assess efficacy, the strategy and design of clinical trials, safety aspects and overall strategy of development.
Keywords: Drug evaluation, drug approval, ulcerative colitis
Current effective version
Guideline on the development of new medicinal products for the treatment of Ulcerative Colitis - Revision 1
English (EN) (255.82 KB - PDF)
Document history
Guideline on the development of new medicinal products for the treatment of Ulcerative Colitis - Revision 1
English (EN) (255.82 KB - PDF)
Overview of comments received on ''Draft guideline on the development of new medicinal products for the treatment of Ulcerative Colitis' (EMA/CHMP/EWP/18463/2006 Rev. 1)
English (EN) (599.19 KB - PDF)
Draft guideline on the development of new medicinal products for the treatment of Ulcerative Colitis - Revision 1
This is the 1st revision of the guideline on the development of new medicinal products for the treatment of Ulcerative Colitis.
The main aim of this 1st revision is to update the guidance on the design of studies in adult patients, especially on potential claims, primary and secondary endpoints and comparators. It is also intended to give further guidance with regards the possibility for extrapolation from adults, or the need to generate separate data in children and to give recommendations regarding the exploration of PK/PD in paediatric drug development.
English (EN) (202.01 KB - PDF)
Draft concept paper on the revision of the guideline on the development of new medicinal products for the treatment of ulcerative colitis
The scope of this planned revision to the guideline on the development of new medicinal products for the treatment of ulcerative colitis was extended to include adult as well as paediatric populations in October 2014. A previous version of this concept paper released for consultation in November 2012 only concerned paediatric populations.
English (EN) (88.49 KB - PDF)
Concept paper on the revision of the guideline on the development of medicinal products for the treatment of ulcerative colitis
The proposed guideline will replace the guideline on the development of medicinal products for the treatment of ulcerative colitis (CHMP/EWP/18463/2006).
English (EN) (131.53 KB - PDF)
Guideline on the development of new medicinal products for the treatment of ulcerative colitis
English (EN) (115.45 KB - PDF)
Overview of comments received on draft guideline on the development of new medicinal products for the treatment of ulcerative colitis
English (EN) (167.47 KB - PDF)
Draft guideline on the development of new medicinal products for the treatment of ulcerative colitis
English (EN) (67.34 KB - PDF)
Related content
- Clinical efficacy and safety: alimentary tract and metabolism
- Directive 2001/83/EC
- Application with 1. Meta-analyses; 2. One pivotal study
- Choice of a non-inferiority margin
- Conduct of pharmacovigilance for medicines used by the paediatric population
- ICH E1 Population exposure: the extent of population exposure to assess clinical safety
- ICH E4 Dose response information to support drug registration
- ICH E6 (R1) Good clinical practice
- ICH E8 General considerations for clinical trials
- ICH E9 Statistical principles for clinical trials
- ICH E10 Choice of control group in clinical trials
- ICH E11 Clinical investigation of medicinal products in the paediatric population
- Investigation of drug interactions
- Regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products